VYNE Therapeutics(VYNE.US)

Last Updated 19:00:00 ET
longbridge loading

Vyne Therapeutics publishes Yarrow Bioscience investor presentation factsheet

PUBT·
US
VYNE
+0.19%
PUBT·
US
VYNE
+0.19%

14:06 ETSHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE, MASI, IBCP, and HCBN

prnewswire·
US
XHE
+0.20%
US
IXJ
+0.67%
US
ARWR
-2.07%
prnewswire·
US
XHE
+0.20%
US
IXJ
+0.67%
US
ARWR
-2.07%

VYNE Therapeutics Granted Nasdaq Extension to Regain Compliance

Tip Ranks·
US
PBE
+0.35%
US
BIB
+1.41%
US
BBH
+0.64%
Tip Ranks·
US
PBE
+0.35%
US
BIB
+1.41%
US
BBH
+0.64%

08:42 ETSYNEVIT® Addresses Hormonal Imbalance Ahead of National Endometriosis Awareness Month

prnewswire·
US
BBH
+0.64%
US
BIB
+1.41%
US
XHE
+0.20%
prnewswire·
US
BBH
+0.64%
US
BIB
+1.41%
US
XHE
+0.20%

Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics

Tip Ranks·
US
HIND
+5.69%
US
VYNE
+0.19%
Tip Ranks·
US
HIND
+5.69%
US
VYNE
+0.19%

Vynleads (OTCQB: VYND) Launches Done With Diabetes™ App, Bringing AI-Powered Daily Lifestyle Support to Blood Sugar and Metabolic Health | VYND Stock News

StockTitan·
US
IHE
+1.29%
US
SBIO
+1.84%
US
PBE
+0.35%
StockTitan·
US
IHE
+1.29%
US
SBIO
+1.84%
US
PBE
+0.35%

Investigation into VYNE Therapeutics Inc. for possible breaches of fiduciary duty in transaction with Yarrow Bioscience.

Unusual Whales·
US
VYNE
+0.19%
Unusual Whales·
US
VYNE
+0.19%

19:39 ET Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

prnewswire·
US
VYNE
+0.19%
prnewswire·
US
VYNE
+0.19%
© 2026 Longbridge｜Disclaimer